WO2009142717A2 - Procédés et produits permettant la dédifférenciation cellulaire - Google Patents

Procédés et produits permettant la dédifférenciation cellulaire Download PDF

Info

Publication number
WO2009142717A2
WO2009142717A2 PCT/US2009/003082 US2009003082W WO2009142717A2 WO 2009142717 A2 WO2009142717 A2 WO 2009142717A2 US 2009003082 W US2009003082 W US 2009003082W WO 2009142717 A2 WO2009142717 A2 WO 2009142717A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
oxygen
days
less
Prior art date
Application number
PCT/US2009/003082
Other languages
English (en)
Other versions
WO2009142717A3 (fr
WO2009142717A8 (fr
Inventor
Arvind Ramanathan
Jacob Hecksher-Sorenson
Stuart L. Schreiber
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of WO2009142717A2 publication Critical patent/WO2009142717A2/fr
Publication of WO2009142717A8 publication Critical patent/WO2009142717A8/fr
Publication of WO2009142717A3 publication Critical patent/WO2009142717A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions

Definitions

  • the invention relates to methods and compositions for producing immature cells, including induced pluripotent stem cells, from more mature cell types.
  • Regenerative medicine relies on the ability to generate one or more cell lineages and/or complete tissues in vitro or in vivo in order to replace defective or non-existent cell lineages and/or tissues in vivo.
  • Regenerative medicine therefore requires cells that are capable of generating these cell lineages and/or tissues. Such cells must have self-renewal capacity and, for most applications, be pluripotent.
  • Self-renewal is the process through which a cell divides and thereby generates at least one cell that is identical to itself, both with respect to self-renewal and differentiative potential. Cells that have self-renewal potential are referred to as stem cells. These cells may be unipotent, multipotent, or pluripotent.
  • Unipotency refers to the ability of the cell to give rise to one lineage.
  • Multipotency refers to the ability of the cell to give rise to two or more, but not all, lineages in the body.
  • Pluripotency refers to the ability of the cell to differentiate into mesoderm, endoderm and ectoderm lineages in the body.
  • Pluripotent cells may in some instances differentiate into all lineages of the body. Cells that are capable of self-renewal and are pluripotent are referred to as pluripotent stem cells.
  • Pluripotent stem cells occur naturally in the process of normal development. Identifying and isolating such cells in numbers that are clinically useful however is difficult. Thus, methods have been established for generating pluripotent stem cells from embryonic cells and tissues and recently from adult cells also. Examples include embryonic stem cells that are generated from the inner cell mass of blastocysts or blastomeres, and stem cells that are generated by transferring a nucleus from an adult somatic cell into an enucleated oocyte followed by chemically induced fertilization (so-called somatic cell nuclear transfer).
  • a major clinical hurdle to using stem cell based therapies to treat human disorder is the need for histocompatibility between the donor cells and the recipient subject.
  • the donor cells and the recipient are autologous. This situation however has been limited in the past to the use of donor cells derived from the recipient subject or from a genetically identical twin of the recipient subj ect.
  • pluripotent stem cells can be generated by reprogramming (or dedifferentiating) adult cells through the induced expression of particular early development gene combinations.
  • Takahashi and Yamanaka reported that primary dermal fibroblasts can be reprogrammed by inducing expression of OCT4, SOX2, KLF4 and cMYC using retroviral transfection. (Takahashi and Yamanaka 2006 Cell 126:663.)
  • iPS induced pluripotent stem
  • the invention relates broadly to the ability to dedifferentiate mature cells into immature cells using hypoxic conditions. More specifically, the invention relates to the ability to produce immature cells, including pluripotent stem cells, from adult somatic cells by exposing such somatic cells to hypoxic conditions.
  • the hypoxic condition may be a low oxygen gas environment in which the cells are placed and/or cultured, or it may be contact and/or exposure to an agent that mimics hypoxia (i.e., a hypoxia-mimicking agent).
  • the invention thereby provides compositions and methods for generating pluripotent stem cells independent of the retroviral transfection methods of the prior art.
  • the invention provides, in one aspect, a method for dedifferentiating an isolated somatic cell from a subject comprising exposing an isolated somatic cell from a subject to a hypoxic condition for a time sufficient to dedifferentiate the isolated somatic cell, and isolating an immature cell derived from the isolated somatic cell.
  • the invention provides in another aspect a method for producing an induced pluripotent stem cell comprising exposing an isolated somatic cell to a hypoxic condition for a time sufficient to produce an induced pluripotent stem cell, and isolating an induced pluripotent stem cell derived from the isolated somatic cell.
  • the isolated somatic cell is an isolated fibroblast.
  • the isolated fibroblast may be an isolated dermal fibroblast, although it is not so limited.
  • the isolated somatic cell is exposed to a hypoxic condition by culturing the isolated somatic cell in a hypoxic condition.
  • the hypoxic condition is a low oxygen gas environment.
  • the low oxygen gas environment may be an oxygen level in a gas phase in contact with culture medium that is less than 15% oxygen or less than 10% oxygen. Alternatively, it may be less than 5% oxygen, less 4% oxygen, less than 3% oxygen, less than 2% oxygen, or less than 1% oxygen. In other embodiments, it may be about 0.05% to about 2% oxygen, about 0.1% to about 1.5% oxygen, or about 0.5% to about 1.5% oxygen, or about 1% oxygen.
  • the hypoxic condition is the presence of a hypoxia-mimicking agent.
  • the hypoxia-mimicking agent may be desferoxamine, deferoxamine, cobalt chloride, S-nitroso-N-acetylcysteine, or 2,2'-dipyridyl, although it is not so limited.
  • the isolated somatic cell is exposed to the hypoxic condition for at least 3 days, at least 6 days, or at least 9 days. In another embodiment, the isolated somatic cell is exposed to the hypoxic condition for at least 12 days, at least 15 days, at least 18 days, or at least 21 days. In yet another embodiment, the isolated somatic cell is exposed to the hypoxic condition for about 5 days to about 22 days. In still another embodiment, the isolated somatic cell is exposed to the hypoxic condition for about 6 days to about 21 days. In still another embodiment, the isolated somatic cell is exposed to the hypoxic condition for about 9 days to about 21 days.
  • the immature cell expresses OCT4. In another embodiment, the immature cell expresses OCT4 and KLF4. In one embodiment, the isolated somatic cell is a normal cell. In another embodiment, the isolated somatic cell is a cancer cell. In important embodiments, the isolated somatic cell is a human cell.
  • the invention provides in a further aspect a composition comprising a population of immature cells or a population of induced pluripotent stem cells produced according to any of the foregoing methods.
  • the population is derived from a normal cell, while in others it is derived from a cancer cell.
  • the population is preferably clonal.
  • the invention provides in still another aspect a method for producing a differentiated cell population comprising culturing the immature cells or induced pluripotent stem cells generated according to any of the foregoing methods for a time and under conditions sufficient to produce differentiated cells of one or more lineages, isolating the differentiated cells.
  • the invention provides in still another aspect a composition comprising a differentiated cell population produced according to any of the foregoing methods.
  • the invention provides an induced pluripotent stem cell that does not contain exogenous nucleic acid.
  • the exogenous nucleic acid is OCT4, SOX2, KLF4, cMYC, LIN28, or NANOG.
  • the invention further provides compositions comprising such cells including pharmaceutical compositions.
  • the invention also provides cultures comprising such cells.
  • the invention provides a method for producing a differentiated cell population comprising culturing these induced pluripotent stem cells for a time and under conditions sufficient to produce differentiated cells of one or more lineages, isolating the differentiated cells.
  • the invention provides an induced pluripotent stem cell that does not contain a retroviral nucleic acid.
  • the invention further provides compositions comprising such cells including pharmaceutical compositions.
  • the invention also provides cultures comprising such cells.
  • the invention provides a method for producing a differentiated cell population comprising culturing these induced pluripotent stem cells for a time and under conditions sufficient to produce differentiated cells of one or more lineages, isolating the differentiated cells.
  • FIG. 1 mRNA levels of transcription factors in panel cells after 0, 3, 6 and 9 days (last 4 columns) of culture under hypoxic conditions (i.e., a gas phase having 1 % oxygen in these experiments), as compared to panel cells grown for the same time under normoxic conditions.
  • FIGs. 2A and 2B BJ cells cultured under normoxic conditions for 20 days maintain their replicative potential and fibroblast morphology (A) while BJ cells cultured under hypoxic conditions (i.e., a gas phase having 1 % oxygen in these experiments) and but then returned to normoxic conditions adopt a rounded morphology and lose contact inhibition (B).
  • FIG. 3. A schematic of one embodiment of the dedifferentiation process of the invention.
  • the invention provides in part methods for generating immature cells from more mature cells independent of exogenous gene expression. More specifically, the invention is based in part on the surprising and unexpected discovery that adult somatic cells can be reprogrammed into more immature cell types, including pluripotent stem cells, through exposure to hypoxia or hypoxic conditions.
  • the immature cell types retain the same genetic makeup as the starting cell population and thus are ultimately autologous (i.e., genetically identical) to the somatic cell donor.
  • These immature cell types may be stem cells, and such stem cells may be unipotent, multipotent or pluripotent.
  • immature cells may be referred to as precursors or precursor cells, and a subset of such precursor cells are stem cells.
  • the invention therefore embraces the methods for generating immature cells from more mature cells, compositions for generating immature cells from more mature cells, compositions of the immature cells generated according to the invention, and methods of use for such cells, including therapeutic and screening methods.
  • the invention is based, in part, on the observation that adult somatic cells can be reprogrammed into immature cells by exposing such cells to hypoxia or hypoxic conditions (e.g., using agents that mimic hypoxia).
  • hypoxia means reduced oxygen level relative to normal oxygen level. This level may be expressed in a number of ways, as discussed in greater detail herein.
  • a hypoxic condition is therefore a condition in which oxygen level is reduced relative to normal oxygen level. Air is normally about 20% oxygen.
  • ⁇ лектрол ⁇ ⁇ лект ⁇ are usually cultured in incubators having a 95% air and 5% CO 2 mixture, resulting in about 19% oxygen. These oxygen levels are considered normal, as used herein. Thus, a below normal oxygen level is one that is less than 20% if the cells are exposed to air, or it is less than 19% if the cells are in an incubator that normally provides the 95%/5% gas phase described above.
  • hypoxic conditions may be induced in a variety of ways.
  • hypoxic conditions may be induced by reducing the oxygen content of the gas with which the cells are in contact. For example, if the cells are being cultured in an incubator, the gas phase within that incubator is adjusted to be less than 19% oxygen.
  • the gas phase may be less than 18% oxygen, less than 17% oxygen, less than 16% oxygen, less than 15% oxygen, less than 14% oxygen, less than 13% oxygen, less than 12% oxygen, less than 11 % oxygen, less than 10% oxygen, less than 9% oxygen, less than 8% oxygen, less than 7% oxygen, less than 6% oxygen, less than 5% oxygen, less than 4% oxygen, less than 3% oxygen, less than 2% oxygen, less than 1% oxygen, less than 0.9% oxygen, less than 0.8% oxygen, less than 0.7% oxygen, less than 0.6% oxygen, less than 0.5% oxygen, less than 0.4% oxygen, less than 0.3% oxygen, less than 0.2% oxygen, less than 0.1% oxygen, less than 0.09% oxygen, less than 0.08% oxygen, less than 0.07% oxygen, less than 0.06% oxygen, or about 0.05% oxygen.
  • the Examples demonstrate the ability to dedifferentiate adult fibroblasts in culture in about 1% oxygen and in about 0.1% oxygen.
  • the oxygen level in the gas phase in contact with the culture media may also be expressed as a range, and in this respect includes about 0.05% to about 5% oxygen, about 0.1% to about 3% oxygen, about 0.5% to about 2% oxygen, and about 1% to about 1.5% oxygen.
  • the gas phase is about 1% oxygen.
  • the term about means +/- 0.5%.
  • Oxygen levels may also be referred to in terms of partial pressure (as measured in mmHg). Oxygen control devices may express oxygen levels as a percentage. p ⁇ 2gas can be determined based on knowledge of a percent oxygen measurement using the following formula:
  • 760 is the atmospheric pressure and 47 is the vapor pressure of water at 37 0 C.
  • Gas phase oxygen concentrations of 1%, 5%, 20%, and 40% correspond to p ⁇ 2gas of 7 mmHg, 36 mmHg, 142 mmHg, and 285 mmHg. Atmospheric p ⁇ 2 is therefore about 142 mmHg.
  • low p ⁇ 2 refers to p ⁇ 2 that is less than atmospheric partial pressure. More specifically, in some embodiments, low p ⁇ 2 refers to a p ⁇ 2 that is less than 142 mmHg.
  • Low p ⁇ 2 therefore may be a p ⁇ 2 that is less than 140 mmHg, less than 135 mmHg, less than 130 mmHg, less than 125 mmHg, less than 120 mmHg, less than 1 15 mmHg, less than 1 10 mmHg, less than 105 mmHg, less than 100 mmHg, less than 95 mmHg, less than 90 mmHg, less than 85 mmHg, less than 80 mmHg, less than 75 mmHg, less than 70 mmHg, less than 65 mmHg, less than 60 mmHg, less than 55 mmHg, less than 50 mmHg, less than 45 mmHg, less than 40 mmHg, less than 35 mmHg, less than 30 mmHg, less than 25 mmHg, less than 20 mmHg, less than 15 mmHg, less than 14 mmHg, less than 13 mmHg, less than 12 mmHg, less
  • p ⁇ 2gas can be regulated during culture using manual and automated devices. Examples of commercially available automated devices include but are not limited to OxyCycler C42 from BioSpherix (Redfield, NY) and MC0-5M from Sanyo (Bensenville, IL).
  • hypoxia-mimicking agents agents that mimic hypoxia.
  • agents that mimic hypoxia may be referred to herein as hypoxia-mimicking agents.
  • agents that reduce histone demethylase activity such as iron chelators and inhibitors of alpha-ketoglutarate can be used as hypoxia-mimicking agents.
  • Inhibitors of other co-factors of histone demethylases can also be used as hypoxia-mimicking agents.
  • hypoxia-mimicking agents include but are not limited to desferoxamine, cobalt chloride, S-nitroso-N-acetylcysteine, and 2,2'-dipyridyl.
  • the adult somatic cells of the invention are any non-germ cell from a non-embryonic, non-fetal subject.
  • the cell may be a normal cell or it may be a cancer cell (e.g., isolated from a biopsy).
  • the cell is one that is easily isolated from the subject.
  • Dermal fibroblast cells therefore are preferred in some instances.
  • Other adult somatic cells include but are not limited to oral fibroblasts, foreskin fibroblasts, breast fibroblasts, and the like . Methods for harvesting such cells are known in the art and the invention is not limited in this regard.
  • the adult somatic cells are isolated. This means that they are harvested and separated from the environment in which they normally exist. Thus, if the adult somatic cells are primary dermal fibroblasts, they are isolated when they are harvested from a subject and exist in vitro.
  • the subjects from whom adult somatic cells can be harvested include human subjects, companion animals such as dogs, cats, ferrets, and the like, agricultural animals such as cows, pigs, horses, sheep, ostriches, and the like, zoo animals such as bears, zebra, giraffes, lions and other wild cat species, and the like, aquatic species such as fish, dolphins, whales, sharks, and the like, and research animals such as mice, rats, rabbits, monkeys, and the like.
  • the immature or precursor cells generated according to the invention are defined as cells which are functionally or genetically more immature than their parent cells (i.e., the adult somatic cell which gave rise to the immature or precursor cell).
  • Functional immaturity is defined, according to the invention, as an increased level of self-renewal and/or more differentiative potential.
  • Self-renewal may be deduced based on an increase in proliferative potential. This may be observed as the capacity to proliferate in cells that had been quiescent and possibly senescent. This may also be observed as a shorter doubling time. Such increases in proliferative potential however should not be confused with malignant transformation in these cells which is usually associated the loss of contact inhibition or factor independent growth.
  • An increase in differentiative potential refers to the ability of the cell to differentiate into a different lineage from that of the mature cell from which it derived.
  • the generation of an immature cell may therefore be shown by the generation of a cell that can differentiate into multiple lineages as demonstrated in in vitro (e.g., embryoid body (EB) formation) or in vivo (e.g., teratoma formation) assays described in Yu et al. Science 2007 318:1917, Park et al. Nature 2008 451(7175): 141 -6, and Takahashi et al. Cell 2006 126:663.
  • Genetic immaturity is defined, according to the invention, as the expression of early markers, optionally concomitant with the loss of expression of more mature markers.
  • Early markers when used in this context refer to genes that are expressed in stem cells or genes that are used to induce stem cells from more mature cells. These markers include OCT4, SOX2, NANOG, KLF4, LIN28, hTERT, SSEAl, and alkaline phosphatase. The expression of these markers may be deduced at the mRNA level (e.g., by Northern or RT-PCR) or at the protein level (e.g., by enzyme assay, by Western analysis, by FACS analysis). The generation of an immature cell may therefore be shown by the generation of a cell that expresses at least one and preferably more of any of these early markers.
  • iPS cells Human iPS cells are defined, according to the invention, as immature cells that resemble human embryonic stem (hES) cells in a number of respects. Morphologically, iPS cells are small round translucent cells that preferably grow in vitro in colonies that are themselves characterized as tightly packed and sharp-edged. Genetically, iPS cells express markers of pluripotency such as OCT4 and NANOG, cell surface markers such as SSEA3, SSEA4, Tra-1-60, and Tra-1-80, and the intracellular enzyme alkaline phosphatase. These cells have a normal karyotype. Their cell cycle profile can be characterized by a short Gl phase, similar to that of hES cells.
  • the terms “dedifferentiating” or “reprogramming” are used interchangeably to refer to the process of generating a relatively more immature cell from a relatively more mature cell. Also as used herein, the terms “generating” and “producing” are used interchangeably.
  • Dedifferentiation may occur through culture of mature cells in hypoxic conditions.
  • the media components are generally dictated by the growth requirements of the mature cell used as the starting cell.
  • the culture conditions may be DMEM (or an equivalent thereof), fetal bovine serum (e.g., 5-10%), nonessential amino acids, and optionally antibiotics.
  • the hypoxic condition results from the use of hypoxia-mimicking agents, the cultures may also contain such agents.
  • a tissue culture solid support e.g., a tissue culture dish or multiwell dish
  • the oxygen level can be reduced immediately regardless of whether the cells are attached to the solid support.
  • the cells are cultured for a period of time sufficient to dedifferentiate them into immature or precursor cells, including iPS cells.
  • the presence of such immature or precursor cells can be determined functionally (e.g., in a differentiation assay) or genetically (e.g., for mRNA analysis of early gene markers).
  • This period of time may be at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 1 1 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, or longer.
  • the culture period is about 6 to about 24 days, about 9 to about 21 days, about 12 to about 18 days, or about 15 days. In some instances, the culture period is about 9 days. In other instances, it is about 21 days.
  • the term about means +/- 0.5 days.
  • the feeder layers consist of cells from the same species as the somatic cells being dedifferentiated.
  • dedifferentiation of a human somatic cell population preferably employs a human feeder cell layer such as a human fibroblast feeder layer.
  • dedifferentiation of a human somatic cell population may employ a mouse embryonic fibroblast (MEF) feeder layer.
  • MEF mouse embryonic fibroblast
  • the feeder cells may in some cases be mitotically inactivated in order to prevent consumption of nutrients by the feeder cells at the expense of the somatic cells and their immature progeny.
  • Mitotic inactivation means that the cells are treated in a manner that prevents them from dividing further but that is not necessarily cytotoxic to the cells.
  • Mitotic inactivation of feeder cells can be accomplished by ultraviolet (UV), X-, or gamma- irradiation (e.g., at 10- 50 Gy), or by chemical means such as senescence inducing drugs (e.g., mitomycin C, toyocamycin, tertbutylhydroperoxide (t-BHP) and hydrogen peroxide (H 2 O 2 )).
  • senescence inducing drugs e.g., mitomycin C, toyocamycin, tertbutylhydroperoxide (t-BHP) and hydrogen peroxide (H 2 O 2 )
  • laminin-coated dishes are used instead of feeder
  • the immature or precursor cells produced by the methods of the invention may also be differentiated in vitro, partially or completely. Differentiation protocols are known in the art and include those described in U.S. Patent Nos. 7,326,572 (endoderm differentiation),
  • Immature or precursors cells may be cultured in the presence of one or more factors and/or chemicals in order to drive differentiation down one or more lineages.
  • factors and/or chemicals in order to drive differentiation down one or more lineages.
  • members of the BMP family of factors have been used to differentiate stem cells such as embryonic stem cells. These include the use of BMP -4 and BMP-7 to generate endoderm-like differentiation.
  • Activin A can be used to differentiate pluripotent stem cells such as embryonic stem cells into definitive endoderm using monolayers or three dimensional (e.g., EB) culture systems.
  • Nervous system cells have been observed as a result of culture with epidermal growth factor and fibroblast growth factor (resulting in the generation of neurospheres that comprise neural stem cells), subsequent removal of these factors (resulting in the generation of astrocyte-like cells) or supplementation with nerve growth factor (resulting in the generation of neurons and glial cells).
  • epidermal growth factor and fibroblast growth factor resulting in the generation of neurospheres that comprise neural stem cells
  • subsequent removal of these factors resulting in the generation of astrocyte-like cells
  • nerve growth factor resulting in the generation of neurons and glial cells.
  • Dopaminergic neurons useful in
  • Parkinson's disease may be formed through culture or contact with FGF20 and FGF2.
  • Hepatic cell differentiation may be induced through contact and/or culture with an insulin, dexamethasone, and collagen type I (via EB formation) combination; a sodium butyrate and DMSO combination; an FGF4, HGF and collagen type I combination; an aFGF, HGF, oncostatin M, dexamethasone and collagen type I combination; and a bFGF, variant HGF, DMSO and dexamethasone combination in the presence of poly-amino-urethane coated non- woven polytetrafluoroethylene fabric.
  • Pancreatic differentiation including differentiation towards beta-islet cells, can be induced using Activin A, retinoic acid, FGF2 and FGFlO, betacellulin, HGF, Exendin 4, DKKl and DKK3.
  • Activin A retinoic acid
  • FGF2 and FGFlO retinoic acid
  • betacellulin HGF
  • Exendin 4 DKKl and DKK3.
  • Endothelial differentiation may be induced in the presence of ECM proteins such as collagen type IV, optionally in the presence of VEGF and bFGF.
  • ECM proteins such as collagen type IV
  • VEGF and bFGF vascular endothelial growth factor
  • the differentiative potential of immature or precursor cells may also be analyzed using in vivo techniques such as teratoma generation (e.g., following subcutaneous or intramuscular injection of the cells, for easy access, observation and harvest of the teratoma).
  • teratoma generation e.g., following subcutaneous or intramuscular injection of the cells, for easy access, observation and harvest of the teratoma.
  • human immature or precursor cells generated according to the invention may be introduced into immuno-comprised mice (e.g., SCID mice) and the resulting teratoma may be analyzed for the presence of endoderm, mesoderm and ectoderm lineages and/or markers.
  • endodermal, mesodermal and ectodermal lineages can be determined via immunohistochemical staining, microscopy (e.g., transmission electron microscopy, TEM), RT-PCR, and the like.
  • microscopy e.g., transmission electron microscopy, TEM
  • RT-PCR RT-PCR
  • the immature cells and/or their differentiated progeny may be used in a variety of in vitro and in vivo methods including but not limited to therapeutic or cosmetic applications, and in vitro screening methods.
  • the immature cells and/or their differentiated progeny may be provided as pharmaceutical compositions that are sterile and appropriate for in vivo use, together with a pharmaceutically acceptable carrier.
  • the cells may be provided as a frozen aliquot of cells, or a culture of cells, in some embodiments including feeder cells also.
  • the immature cells and/or their differentiated progeny will be a clonal population.
  • These cells may further be included in a kit that additionally comprises at a minimum instructions for use of the cells, and optionally comprises one or more other agents whether active (such as for example a hypoxia-mimicking agent) or inactive.
  • the cells may be used alone or together with another agent, whether active or inactive, including but not limited to a differentiating agent, a scaffold, a matrix, and the like.
  • a pharmaceutically-acceptable carrier means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients.
  • Pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers and other materials which are well-known in the art. Such preparations may routinely contain salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.
  • the immature cells and/or their differentiated progeny may be formulated for local or systemic administration including as part of an implant.
  • the invention further contemplates methods for screening agents (or compounds, as the terms are used interchangeably herein) for toxicity and in some embodiments therapeutic efficacy.
  • the readouts from such in vitro assays are correlative of the in vivo toxicity or efficacy such agents would exhibit in human subjects.
  • the effect of the agent on the differentiated cells generated according to the invention in vitro is a form of surrogate marker or readout for how the agent will function in vivo in a human subject.
  • the cells generated according to the invention are autologous to a subject, it is possible to personalize a particular medical treatment based on the response (or lack thereof) of the immature cells and/or their differentiated progeny to the agent being tested.
  • the invention contemplates dedifferentiating somatic cells from subjects having or at risk of developing a condition into immature cells such as iPS cells, and then differentiating these immature cells into the lineages that are affected by the particular condition.
  • the final differentiated cell population may then be used directly (for example, in a transplant) or they may be used as a screening tool to identify therapies for the subject.
  • dermal fibroblasts from a subject having Parkinson's disease are dedifferentiated into iPS cells and the iPS cells are then differentiated into neural cells.
  • the neural cells so generated can be transplanted into the donor subject or they can be used to screen for therapies useful to treat such donor.
  • This therapeutic or screening process can be applied to any number of conditions including other neurodegenerative conditions (e.g.,
  • hematopoietic malignancies e.g., leukemia, lymphoma and the like, particularly where such malignancies are the result of contact or exposure to carcinogens such as radiation
  • degenerative liver conditions e.g., Alzheimer's, ALS, and the like
  • hematopoietic malignancies e.g., leukemia, lymphoma and the like, particularly where such malignancies are the result of contact or exposure to carcinogens such as radiation
  • the immature cells generated by the invention can also be used to screen for agents that promote or drive self-renewal or differentiation into particular lineages.
  • Agents that promote self-renewal would allow for greater numbers of precursor cells to be generated and could be applied to any precursor population (including primary precursor and stem cell populations) and not just those generated according to the methods described herein.
  • Agents that promote differentiation into particular lineages would be useful for preparing cells of particular lineages, to be used in turn therapeutically or for screening purposes.
  • such testing will focus on the toxicity of agents in particular differentiated progeny. Accordingly, in these assays, the readout would be cell death (or conversely cell viability).
  • These in vitro assays may employ suspensions of differentiated cells, adherent populations of differentiated cells, or three dimensional structures comprised of differentiated cells (e.g., in vitro organ tissues, matrices and architectures).
  • the immature cells generated according to the invention may be differentiated into liver cells and thereby used to generate an ex vivo liver that can be used to assay the liver toxicity or liver metabolism of one or more agents.
  • agents include those already used clinically (e.g., in the case of establishing a personalized treatment for a particular subject), as well as those in development (e.g., in the case of identifying a novel agent for the treatment of a disorder).
  • agents may be provided in an isolated form but are not so limited. They may be provided as library members, such as for example small molecules present in a library to be screened according to the invention.
  • the agents may be naturally occurring or non-naturally occurring.
  • Drugs that can be tested according to these methods particularly for whether they are toxic to cells include but are not limited to adrenergic agent; adrenocortical steroid; adrenocortical suppressant; aldosterone antagonist; anabolic; analeptic; analgesic; androgen; anesthesia, adjunct to; anesthetic; anorectic; anterior pituitary suppressant; anti-acne agent; anti-adrenergic; anti-allergic; anti-androgen; anti-anemic; anti-anginal; anti-arthritic; antiasthmatic; anti-atherosclerotic; anticholelithic; anticholelithogenic; anticholinergic; anticoagulant; anticoccidal; anticonvulsant; antidepressant; antidiabetic; antidiarrheal; antidiuretic; anti-emetic; anti-epileptic; anti-estrogen; antifibrinolytic; antiglaucoma agent;
  • BJ primary human foreskin
  • pancreatic ductal cancer panel cells
  • markers of pluripotency namely OCT4, KLF4, SOX2 (and PDXl in the case of panel cells)
  • iPS induced pluripotent stem
  • the method does not involve the integration or transfer of exogenous DNA into the recipient cell.
  • OCT4 reprogramming transcription factors
  • the hypoxic conditions are believed to affect cellular physiology thereby resulting in full reprogramming of somatic cells such as skin cells into iPS cells. All cells derive their energy ultimately from atmospheric oxygen, which is used as a fuel for oxidative metabolism in mammalian cells.
  • Small molecules that affect the way that cells perceive their energy status induce a global switch of metabolism from an oxidative to a glycolytic state, in part by upregulating protein levels of key transcriptional regulators such as HIFl -alpha and HIF2- alpha.
  • This switch results in the down regulation of mitochondrial citric-acid cycle metabolites such as alpha-ketoglutarate.
  • Both iron and alpha-ketoglutarate are important cofactors of histone demethylases and other protein hydroxylases, which are enzymes critical for modulating the epigenetic state of cells.
  • Highly proliferative cells like stem cells have a highly glycolytic metabolism.
  • Examples include 5-aza-deoxycytidine, 5- azacytidine, 5-aza-2'deoxycytidine (also known as Decitabine in Europe), 5, 6-dihydro-5- azacytidine, 5, 6-dihydro-5-aza-2'deoxycytidine, 5-fluorocytidine, 5-fluoro-2'deoxycytidine, and short oligonucleotides containing 5-aza-2'deoxycytosine, 5, 6-dihydro-5-aza- 2'deoxycytosine, and 5-fluoro-2'deoxycytosine.
  • human dermal fibroblasts were initially seeded in 6 well tissue culture dishes at a density of 15000 cells per well.
  • the oxygen level was reduced to either 0.1% or 1% at the beginning of the culture period, without any intervening culture period necessary to allow the fibroblasts to attach to the dish surface.
  • the media on the cells was changed about every 3 days.
  • the cells started to become contact inhibited by about 6 days at which point they were harvested and split (e.g., the cells were diluted about 10 fold).
  • the culture period was 21 days, although cells were harvested from the culture starting at day 6 and at various times thereafter for analysis. 800,000 cells are lysed and RNA is prepared using the Qiagen RNeasy Kit according to manufacturer's instructions.
  • Quantitative PCR was carried out using Applied Biosystems High Capacity cDNA Reverse Transcription Kit (for generating cDNA from isolated RNA from cells) according to manufacturer's instructions. Primers used in the quantitative PCR methods are as described by Yamanaka et al. Cell. 2007 Nov 30;131(5):861-72 and are shown below.
  • hOCT3/4-S1165 GAC AGG GGG AGG GGA GGA GCT AGG (SEQ ID NO:1) hOCT3/4-AS1283 CTT CCC TCC AAC CAG TTG CCC CAA AC (SEQ ID NO: 2) hSOX2-S1430 GGG AAA TGG GAG GGG TGC AAA AGA GG (SEQ ID NO: 3) hSOX2-AS1555 TTG CGT GAG TGT GGA TGG GAT TGG TG ( SEQ ID NO : 4 ) h-NANOG CAG CCC CGA TTC TTC CAC CAG TCC C
  • the fibroblast BJ cells when exposed to 1% oxygen initially retained their fibroblast- like morphology and replicative potential as compared to normoxic conditioned cells that were grown in parallel. After incubating in the presence of 1% oxygen and then returning the cells to untreated (i.e., normoxic) conditions, the cells adopted a rounded morphology and grew in colonies similar to pre-iPS cells. They also adopted a more glycolytic nature as judged by increased lactate production. Representative images of cells and colonies are provided as FIG. 2. Similar results were observed when the cells were exposed to 0.1% oxygen. After 6 days of culture under hypoxic conditions, BJ cells expressed approximately 5 times more OCT4 and SOX2 than untreated (i.e., normoxic) BJ cells.
  • BJ cells express relatively high basal levels of KLF4 normally. No changes were observed in cMYC levels upon incubating BJ cells under these hypoxic conditions, although increased cMYC levels were observed in panel cells so treated. (FIG. 1.) Equivalents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des procédés et des compositions permettant la dédifférenciation de cellules somatiques adultes, ce qui génère des cellules plus immatures, dont des cellules souches pluripotentes.
PCT/US2009/003082 2008-05-19 2009-05-19 Procédés et produits permettant la dédifférenciation cellulaire WO2009142717A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5443008P 2008-05-19 2008-05-19
US61/054,430 2008-05-19

Publications (3)

Publication Number Publication Date
WO2009142717A2 true WO2009142717A2 (fr) 2009-11-26
WO2009142717A8 WO2009142717A8 (fr) 2010-04-08
WO2009142717A3 WO2009142717A3 (fr) 2010-08-19

Family

ID=41340720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/003082 WO2009142717A2 (fr) 2008-05-19 2009-05-19 Procédés et produits permettant la dédifférenciation cellulaire

Country Status (1)

Country Link
WO (1) WO2009142717A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039338A1 (en) * 2008-07-30 2011-02-17 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2011140323A1 (fr) * 2010-05-07 2011-11-10 Fibrocell Science, Inc. Formulations d'unités de dosage de fibroblastes dermiques autologues
WO2022093665A1 (fr) * 2020-10-26 2022-05-05 University Of Massachusetts Procédés et compositions pour le traitement de maladies musculaires avec des cellules souches de muscles squelettiques humains induites par les ipsc

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069666A1 (fr) * 2005-12-13 2007-06-21 Kyoto University Facteur de reprogrammation nucleaire

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069666A1 (fr) * 2005-12-13 2007-06-21 Kyoto University Facteur de reprogrammation nucleaire

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EZASHI, T. ET AL.: 'Low 02 tensions and the prevention of differentiation of hES cells.' PROC. NAT'L ACAD. SCI. vol. 29, 29 March 2005, pages 4783 - 4788 *
HANSIS, C. ET AL.: 'Nuclear Reprogramming of Human Somatic Cells by Xenopus Egg Extract Requires BRG1.' CURRENT BIOL. vol. 14, 24 August 2004, pages 1475 - 1480 *
PARK, I.H. ET AL.: 'Reprogramming of human somatic cells to pluripotency with defined factors' NATURE vol. 451, 10 January 2008, pages 141 - 148 *
STADTFELD, M. ET AL.: 'Defining Molecular Cornerstones during Fibrobalst to iPS cell Reprogramming in Mouse.' CELL STEM CELL, MAR. vol. 2, 2008, pages 230 - 240 *
YOSHIDA, Y. ET AL.: 'Hypoxia Enhances the Generation of Induced Pluripotent Stem Cells.' CELL STEM CELL vol. 5, 04 September 2009, pages 237 - 241 *
YU, J. ET AL.: 'Induced Fluripotent Stem Cell Lines Derived from Human Somatic Cells' SCIENCE vol. 318, 2007, pages 1917 - 1919 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039338A1 (en) * 2008-07-30 2011-02-17 Kyoto University Method of efficiently establishing induced pluripotent stem cells
EP2307539A1 (fr) * 2008-07-30 2011-04-13 Kyoto University Procédé pour établir de manière efficace des cellules souches pluripotentes induites
EP2307539A4 (fr) * 2008-07-30 2012-10-24 Univ Kyoto Procédé pour établir de manière efficace des cellules souches pluripotentes induites
US9528092B2 (en) 2008-07-30 2016-12-27 Kyoto University Methods of efficiently establishing induced pluripotent stem cells under hypoxic conditions
WO2011140323A1 (fr) * 2010-05-07 2011-11-10 Fibrocell Science, Inc. Formulations d'unités de dosage de fibroblastes dermiques autologues
US11554142B2 (en) 2010-05-07 2023-01-17 Castle Creek Biosciences, Llc Dosage unit formulations of autologous dermal fibroblasts
WO2022093665A1 (fr) * 2020-10-26 2022-05-05 University Of Massachusetts Procédés et compositions pour le traitement de maladies musculaires avec des cellules souches de muscles squelettiques humains induites par les ipsc

Also Published As

Publication number Publication date
WO2009142717A3 (fr) 2010-08-19
WO2009142717A8 (fr) 2010-04-08

Similar Documents

Publication Publication Date Title
US20210278395A1 (en) Human trophoblast stem cells and uses thereof
CN103396993B (zh) 衍生自灵长类胚胎干细胞的用于脊髓损伤的再髓鞘化和治疗的少突胶质细胞
AU2002247875B2 (en) Transfection of human embryonic stem cells
WO2002051980A9 (fr) Cellules souches adultes multipotentes derivees in vitro et leurs utilisations
CN101341245A (zh) 获取祖细胞系的方法
US10179901B2 (en) Methods and compositions for increased safety of stem cell-derived populations
CN102186969A (zh) 由人多能干细胞制备人皮肤替代品的方法
AU2002247875A1 (en) Transfection of human embryonic stem cells
Jurga et al. Neurogenic potential of human umbilical cord blood: Neural‐like stem cells depend on previous long‐term culture conditions
Zheng et al. In vitro propagation of male germline stem cells from piglets
H Parsons et al. Patents on technologies of human tissue and organ regeneration from pluripotent human embryonic stem cells
Gerlach et al. Current state of stem cell research for the treatment of Parkinson's disease
WO2009142717A2 (fr) Procédés et produits permettant la dédifférenciation cellulaire
US7763463B2 (en) Use of cyclic AMP and ascorbic acid to produce dopaminergic neurons from embryonic stem cells
EP3875580A1 (fr) Procédés de préparation de kératinocytes
Li et al. Bovine male germline stem-like cells cultured in serum-and feeder-free medium
Kidwai et al. Differentiation of epidermal keratinocytes from human embryonic stem cells
Nehlin et al. Strategies for future histocompatible stem cell therapy
Xu et al. Road to future: iPSC clinical application in Parkinson’s disease treatment
Baudyšová Isolated Organs and Explanted Tissue
CN116769695A (zh) 从畸胎瘤、类器官和拟胚体中产生人细胞和组织的培养基和方法
Williams Bioprocessing of Human Embryonic Stem Cells for the Treatment of Parkinson’s
Ebrahimi Hafshajani et al. Pancreas Extract Induces Differentiation of P19 Embryonic Stem Cells to Insulin-Producing Cells.
Li et al. Advances in stem cell research
IL165645A (en) Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09750948

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09750948

Country of ref document: EP

Kind code of ref document: A2